VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation

Table 2 Treatment costs for the three screening groups

Cost (RMB)	VIA/VILI	TCT	HPV test
Early-treatment cost
Direct medical cost	24150.0	5650.0	82673.3
Direct non-medical cost	1395.9	289.1	1661.5
Indirect cost	11143.4	2307.5	13263.3
Total	36689.3	8246.6	97598.1
Non-early treatment cost
Direct medical cost	379939.8	63323.3	316616.5
Direct non-medical cost	3708.3	618.1	3090.3
Indirect cost	29603.3	4933.9	24669.4
Total	413251.4	68875.3	344376.2

Direct medical cost refers to the cost of medical resource consumption. Direct non-medical cost refers to the cost of diet, accommodation, transportation and communication. Indirect cost refers to the cost of workforce productivity losses. The non-early treatment cost was the cost of cervical cancer treatment for patients who were screened to be ≥ CIN2 (we assumed these patients did not receive intervention, and they developed a cervical cancer)

ISSN: 1471-2458